US Patent Issued to The University of Hong Kong on Sept. 29 for "Use of LANCL1 and antibodies thereof as a diagnostic and therapeutic target for the management and treatment of cancer" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,301, issued on Sept. 29, was assigned to The University of Hong Kong (Hong Kong).

"Use of LANCL1 and antibodies thereof as a diagnostic and therapeutic target for the management and treatment of cancer" was invented by Irene Oi Lin Lui Ng (Hong Kong) and Yu Man Tsui (Hong Kong).

According to the abstract* released by the U.S. Patent & Trademark Office: "The subject invention pertains to antibodies that target LANCL1. The anti-LANCL1 antibodies can be used in methods of treating cancer, including hepatocellular carcinoma. The anti-LANCL1 antibody can be used as a therapeutic regimen for treatment or as part of a combination treatment. Further, the anti-LANCL1 antibodies may also ...